Canaccord Genuity Reaffirms Their Hold Rating on Smith & Nephew Snats (SNN)
Canaccord Genuity analyst Caitlin Roberts maintained a Hold rating on Smith & Nephew Snats today and set a price target of $34.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roberts covers the Healthcare sector, focusing on stocks such as Smith & Nephew Snats, AxoGen, and Establishment Labs Holdings. According to TipRanks, Roberts has an average return of -4.8% and a 50.00% success rate on recommended stocks.
Smith & Nephew Snats has an analyst consensus of Hold, with a price target consensus of $35.75.
Based on Smith & Nephew Snats’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.99 billion and a net profit of $295.65 million. In comparison, last year the company earned a revenue of $2.83 billion and had a net profit of $214 million
Read More on SNN:
Disclaimer & DisclosureReport an Issue
- Smith & Nephew price target lowered to 1,482 GBp from 1,563 GBp at Morgan Stanley
- Smith & Nephew downgraded to Sector Perform from Outperform at RBC Capital
- Smith & Nephew Snats: Hold Rating Amid Strategic Ambitions and Execution Risks
- Smith & Nephew: Poised for Growth with Strategic Investments and Strong Product Pipeline
- Smith+Nephew Unveils RISE Strategy and 2028 Financial Targets
